skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: Gale Academic OneFile Select remover idioma: Russo remover Springer Nature - Springer Journals All 2022 remover IngentaConnect Journals remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

Miles, David ; Baselga, José ; Amadori, Dino ; Sunpaweravong, Patrapim ; Semiglazov, Vladimir ; Knott, Adam ; Clark, Emma ; Ross, Graham ; Swain, Sandra M.

Breast cancer research and treatment, 2013-11, Vol.142 (1), p.89-99 [Periódico revisado por pares]

Boston: Springer US

Texto completo disponível

Citações Citado por
2
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

Cristofanilli, Massimo ; Johnston, Stephen R. D. ; Manikhas, Alexey ; Gomez, Henry L. ; Gladkov, Oleg ; Shao, Zhimin ; Safina, Sufia ; Blackwell, Kimberly L. ; Alvarez, Ricardo H. ; Rubin, Stephen D. ; Ranganathan, Sulabha ; Redhu, Suman ; Trudeau, Maureen E.

Breast cancer research and treatment, 2013, Vol.137 (2), p.471-482 [Periódico revisado por pares]

Boston: Springer US

Texto completo disponível

Citações Citado por
3
Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations
Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations
Material Type:
Artigo 		Adicionar ao Meu Espaço

Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations

Prokofyeva, Darya ; Bogdanova, Natalia ; Dubrowinskaja, Natalia ; Bermisheva, Marina ; Takhirova, Zalina ; Antonenkova, Natalia ; Turmanov, Nurzhan ; Datsyuk, Ihor ; Gantsev, Shamil ; Christiansen, Hans ; Park-Simon, Tjoung-Won ; Hillemanns, Peter ; Khusnutdinova, Elza ; Dörk, Thilo

Breast cancer research and treatment, 2013-01, Vol.137 (2), p.533-539 [Periódico revisado por pares]

Boston: Springer US

Texto completo disponível

Citações Citado por
4
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology

Garnett, Sally Anne ; Martin, Miguel ; Jerusalem, Guy ; Petruzelka, Lubos ; Torres, Roberto ; Bondarenko, Igor N. ; Khasanov, Rustem ; Verhoeven, Didier ; Pedrini, José L. ; Smirnova, Iva ; Lichinitser, Mikhail R. ; Pendergrass, Kelly ; Lindemann, Justin P. O. ; Di Leo, Angelo

Breast cancer research and treatment, 2013-02, Vol.138 (1), p.149-155 [Periódico revisado por pares]

Boston: Springer US

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.